Artificial Intelligence (AI) In Precision Medicine Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Precision Medicine Market 

5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Precision Medicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence (AI) in Precision Medicine Market, By Technology

8.1. Artificial Intelligence (AI) in Precision Medicine Market, by Technology, 2023-2032

8.1.1 Machine Learning

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Querying Method

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Deep Learning

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Deep Learning

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Context-Aware Processing

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Natural Language Processing

8.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Artificial Intelligence (AI) in Precision Medicine Market, By Component

9.1. Artificial Intelligence (AI) in Precision Medicine Market, by Component, 2023-2032

9.1.1. Hardware

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Software

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Service

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Artificial Intelligence (AI) in Precision Medicine Market, By Therapeutic Application 

10.1. Artificial Intelligence (AI) in Precision Medicine Market, by Therapeutic Application, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Neurology

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Cardiology

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Respiratory

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Artificial Intelligence (AI) in Precision Medicine Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2020-2032)

11.1.2. Market Revenue and Forecast, by Component (2020-2032)

11.1.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2020-2032)

11.2.2. Market Revenue and Forecast, by Component (2020-2032)

11.2.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Component (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Component (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2020-2032)

11.3.2. Market Revenue and Forecast, by Component (2020-2032)

11.3.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Component (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Component (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Component (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Component (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Component (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Component (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Therapeutic Application (2020-2032)

Chapter 12. Company Profiles

12.1. Novo Nordisk A/S

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GE Healthcare

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Intel Corporation

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. NVIDIA Corporation

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Microsoft Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Alphabet Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. IBM Corporation

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. BioXcel Therapeutics Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Enlitic Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AstraZeneca

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms